Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children

Journal of Infectious Diseases

Volumn 210, Issue 2, 2014, Pages 224-233

  Cao, Raquel G ^a   Suarez, Nicolas M ^a   Obermoser, Gerlinde ^c   Lopez, Santiago M C ^a   Flano, Emilio ^a   Mertz, Sara E ^a   Albrecht, Randy A ^d,e   García Sastre, Adolfo ^d,e,f   Mejias, Asuncion ^a,b   Xu, Hui ^c   Qin, Huanying ^c   Blankenship, Derek ^c   Palucka, Karolina ^c   Pascual, Virginia ^c   Ramilo, Octavio ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^d Baylor Institute for Immunology Research Baylor Research Institute ^*  (United States)

^e Global Health and Emerging Pathogens Institute   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

neutralizing antibodies

Indexed keywords

INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INTERFERON; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMORAL IMMUNITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; KINETICS; MALE; MEMORY CELL; NUCLEOTIDE SEQUENCE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

CHILDREN; HI ANTIBODIES; INFLUENZA VACCINE; INTERFERON; LAIV; NEUTRALIZING ANTIBODIES; TIV;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERONS; MALE; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84903949986     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu079     Document Type: Article

References (36)

1. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342:232-9. (Pubitemid 30058954)
2. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002; 185:147-52. (Pubitemid 34056437)
3. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis 2004; 190:1369-73. (Pubitemid 39332175)
4. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006; 355:31-40.
5. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
6. Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 2005; 23:2851-61. (Pubitemid 40386486)
7. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 2009; 27:1101-10.
8. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 2004; 23:189-97.
9. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008: CD004879.
10. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9. (Pubitemid 44510578)
11. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9. (Pubitemid 44510577)
12. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
13. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-71. (Pubitemid 351769295)
14. Wang S, Taaffe J, Parker C, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006; 80:11628-37. (Pubitemid 44788877)
15. Steel J, Lowen AC, Pena L, et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 2009; 83:1742-53.
16. Brady RC, Treanor JJ, Atmar RL, et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009; 27:5091-5.
17. KeitelWA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008; 198:1309-16.
18. Center for Biologics Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. US Department of Health and Human Services, FDA, Rockville, MD 2007; 1-16.
19. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
20. Banchereau R, Jordan-Villegas A, Ardura M, et al. Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections. PLoS One 2012; 7:e34390.
21. Allantaz F, Chaussabel D, Stichweh D, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007; 204: 2131-44. (Pubitemid 47360874)
22. Ramilo O, Allman W, Chung W, et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 2007; 109:2066-77. (Pubitemid 46348207)
23. Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29:150-64. (Pubitemid 351952461)
24. Wang L, Chen X,Wolfinger RD, Franklin JL, Coffey RJ, Zhang B. A unified mixed effects model for gene set analysis of time course microarray experiments. Stat Appl Genet Mol Biol 2009; 8:1-18.
25. Obermoser G, Presnell S, Domico K, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013; 38:831-44.
26. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81:215-28. (Pubitemid 44975162)
27. Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011; 12:786-95.
28. Lee MS, Mahmood K, Adhikary L, et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 2004; 23:852-6. (Pubitemid 40221030)
29. Veguilla V, Hancock K, Schiffer J, et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in US populations. J Clin Microbiol 2011; 49:2210-5.
30. Papenburg J, Baz M, Hamelin ME, et al. Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol 2011; 18:520-2.
31. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7. (Pubitemid 30194502)
32. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157-60. (Pubitemid 16090261)
33. Ambrose CS, Wu X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 2012; 30: 6794-801.
34. Barria MI, Garrido JL, Stein C, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013; 207:115-24.
35. ZhuW, Higgs BW, Morehouse C, et al. Awhole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 2010; 28:2865-76.
36. Bucasas KL, Franco LM, Shaw CA, et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011; 203:921-9.